| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -2.2 | -2.3 |
| Net income | -2.2 | -2.3 |
| EPS (diluted, $ a share) | $-0.24 | $-0.27 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: EXOZ. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Exozymes Inc.: key numbers
- Share price
- $3.99Close, Nov 16
- Market cap
- $37.7M
- Shares outstanding
- 9.44MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Exozymes Inc.
All →Exozymes Chief Commercial Officer Damien Alan Perriman Sells $19.4K of Stock
Damien Alan Perriman, Chief Commercial Officer, sold 3,729 shares of Exozymes Inc. at $5.21 a share, worth $19.4K in total on Oct 12, 2026. Shares held after the trade: 28,692 (-11.5%).
- Value
- $19.4K
- Shares
- 3,729
- Price
- $5.21
- Role
- Chief Commercial Officer
- Holding change
- -11.5%
- Trade date
- Oct 12, 2026
Exozymes Investor Presentation
eXoZymes Inc. filed a formal Investor Presentation dated October 6, 2026, to be shared with investment bankers and potential investors. The presentation provides strategic highlights and business updates for the company's current and future stakeholders.
Exozymes Shareholder Meeting
Exozymes Inc. has scheduled its 2026 Annual Meeting of Shareholders for November 13, 2026. The company established a record date of September 15, 2026, and plans to distribute proxy materials to shareholders on or about September 28, 2026.